代谢功能障碍相关脂肪性肝病的纵向结局:129项研究的Meta分析
该Meta分析纳入129项原始研究,比较MASLD患者与非MASLD个体的纵向临床结局风险。结果显示MASLD患者心血管结局、高血压、糖尿病、糖尿病前期、代谢综合征、慢性肾脏病及所有癌症风险均显著升高;合并晚期肝病的MASLD患者发生糖尿病的风险显著高于较轻MASLD患者。
要点
- MASLD患者心血管结局风险升高(HR 1.43,95%CI 1.27-1.60,P<.01)。
- MASLD患者糖尿病风险升高(HR 2.56,95%CI 2.10-3.13,P<.01)。
- 合并晚期肝病的MASLD患者糖尿病风险高于较轻MASLD患者(HR 3.60 vs 1.63,P=.02)。
核心结论
- 本研究强调MASLD与其临床结局(包括心血管、代谢、肿瘤及其他结局)相关。
- 分析发现的MASLD多系统性质要求治疗目标应减少全身性事件和终末器官并发症。
研究设计与样本
- 检索Medline和Embase数据库,纳入评估MASLD患者与非MASLD个体相比新发临床结局纵向风险的原始研究。
- 采用DerSimonian Laird随机效应Meta分析,计算合并效应估计并评估研究间异质性。
- 共纳入129项研究。
主要发现
- MASLD患者心血管结局风险显著升高(HR 1.43,95%CI 1.27-1.60,P<.01)。
- MASLD患者高血压风险升高(HR 1.75,95%CI 1.46-2.08,P<.01);糖尿病风险升高(HR 2.56,95%CI 2.10-3.13,P<.01);糖尿病前期风险升高(HR 1.69,95%CI 1.22-2.35,P<.01)。
- MASLD患者代谢综合征风险升高(HR 2.57,95%CI 1.13-5.85,P=.02);慢性肾脏病风险升高(HR 1.38,95%CI 1.27-1.50,P<.01);所有癌症风险升高(HR 1.54,95%CI 1.35-1.76,P<.01)。
- 亚组分析显示,与非MASLD相比,合并晚期肝病的MASLD患者发生糖尿病的风险(HR 3.60,95%CI 2.10-6.18,P<.01)显著高于较轻MASLD患者(HR 1.63,95%CI 1.0-2.45,P=.02),组间比较P=.02。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The progression of metabolic dysfunction-associated steatotic liver disease (MASLD) has been found to manifest in a series of hepatic and extrahepatic complications. A comprehensive meta-analysis of the longitudinal outcomes associated with MASLD has yet to be conducted. METHODS: To investigate the longitudinal outcomes associated with MASLD, Medline and Embase databases were searched to identify original studies that evaluated the longitudinal risks of incident clinical outcomes among MASLD patients compared with non-MASLD individuals. DerSimonian Laird random-effects meta-analysis was performed. Pooled effect estimates were calculated, and heterogeneity among studies was evaluated. RESULTS: One hundred twenty-nine studies were included in the meta-analysis. Meta-analysis revealed a significant increase in the risk of cardiovascular outcomes (hazard ratio [HR], 1.43; 95% confidence interval [CI], 1.27-1.60; P < .01), various metabolic outcomes such as incident hypertension (HR, 1.75; 95% CI, 1.46-2.08; P < .01), diabetes (HR, 2.56; 95% CI, 2.10-3.13; P < .01), pre-diabetes (HR, 1.69; 95% CI, 1.22-2.35; P < .01), metabolic syndrome (HR, 2.57; 95% CI, 1.13-5.85; P = .02), chronic kidney disease (HR, 1.38; 95% CI, 1.27-1.50; P < .01), as well as all cancers (HR, 1.54; 95% CI, 1.35-1.76; P < .01) among MASLD patients compared with non-MASLD individuals. By subgroup analysis, MASLD patients with advanced liver disease (HR, 3.60; 95% CI, 2.10-6.18; P < .01) were also found to be associated with a significantly greater risk (P = .02) of incident diabetes than those with less severe MASLD (HR, 1.63; 95% CI, 1.0-2.45; P = .02) when compared with non-MASLD. CONCLUSIONS: The present study emphasizes the association between MASLD and its clinical outcomes including cardiovascular, metabolic, oncologic, and other outcomes. The multisystemic nature of MASLD found in this analysis requires treatment targets to reduce systemic events and end organ complications.
引用
- Chan KE, Ong EYH, Chung CH, et al. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies. Clin Gastroenterol Hepatol. 2023. PMID: 37775028. doi:10.1016/j.cgh.2023.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。